FIELD: chemistry.
SUBSTANCE: present invention refers to the field of organic chemistry, notably to derivatives of dihydroimidazole with the general formula (I) and to its pharmaceutically acceptable salts where X1 and X2 denote halogen; R1 and R2 are chosen from the group including -H, -CH3, -CH2CH3 on the condition that both R1 and R2 do not denote hydrogen; R3 denotes -H or -C(=O)-R7; and if R6 denotes hydrogen, then R4 denotes -OCH3, -OCH2CH3 or -OCH(CH3)2; R5 denotes -H, - halogen, -CF3, -OCH3, -C(CH3)2, - cyclopropyl, - cyano group, -C(CH3)3, -C(CH3)2OR (where R denotes -H), -C(CH3)2CH-OR (where R denotes -CH3), -C(CH3)2CN, -C(CH3)2COR (where R denotes -CH3), -SR (where R denotes -CH2CH3) or -SO2R (where R denotes -CH3, -CH2CH3, 1-pyrrolidine, -NH-tert-butyl); and if R6 does not denote hydrogen, then R4 denotes -OCH2CH3; R5 denotes hydrogen, -Cl, -OCH3, tert butyl; R6 denotes -Cl, cyclopropyl, -SO2R (where R denotes -CH3, 1-pyrrolidine, -NH-tert-butyl or -N(CH3)2); and R7 is chosen from the group including i) -CH3, -CH(CH3)2, -CH2CH(CH3)2, cyclopropyl, cyclobutyl, -CH2CH2Ph, 2-furanyl, phenyl or phenyl substituted with chlorine, -OCH3 or cyano group, ii) 1-piperidinyl, iii) -NRc 2 (where Rc denotes -CH2CH2OH, -CH2CH2OCH3 or -CH2CH(OH)CH2OH, iv) substituted piperazidine with the formula 
where R is chosen from the group including a) hydrogen, c) -CH(CH3)2, k) -CH2CH2Rd (where Rd denotes -OH, -OCH3, -CF3, -SO2CH3, -NH2, -NHCOCH3, -NHSO2CH3, 4-morfolinil, 2-izotiazolidinil-1, 1-dioxide), l) -CH2CH2CH2Re (where Re denotes -OCH3, -SO2CH3, -SO2CH2CH3, -CN), m) -CH2-CO-Rh (where Rh denotes -NH2, 1-pyrrolidinyl, 4-morfolinil), n) -SO2Ri (where Ri denotes -CH3, -CH2CH3), o) -CORj (where Rj denotes -CH3, 2-tetrahydrofuranyl, -NH2, -N(CH3)2), p) 4-tetrahydro-2H-thiopiranyl-1,1-dioxide, q) 4-piperidinyl-1-acetyl, r) 4-piperidinyl-1-dimethylcarboxamide, and s) 3-tetrahydrothiophenyl-1,1-dioxide; v) substituted oxopiperazine with the formula 
where R denotes -H; and vi) substituted piperidine with the formula 
where R denotes -CONH2, -OH, -CH2OH, -CH2CH2OH, 1-pyrrolidinyl, 1-piperidinyl, 1-(4-methylpiperazinyl) or 4-morfolinil. Moreover, the invention refers to the pharmaceutical composition based on the compound with the formula (I), to application of the formula (I) compound for production of a drug, to the production process of the formula (I) compound. 
EFFECT: new derivatives of dihydroimidazole that may be used as anticancer drugs.
40 cl, 204 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CIS-2,4,5-TRIARYLIMIDAZOLINES AND USE THEREOF AS ANTICANCER MEDICINAL AGENTS | 2006 |
|
RU2411238C2 |
| CHIRAL CIS-IMIDAZOLINES | 2008 |
|
RU2487127C2 |
| NEW CIS-IMIDAZOLINES | 2005 |
|
RU2408593C2 |
| CIS-2,4,5-TRIPHENYLIMIDAZOLINES AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2305095C2 |
| CIS-IMIDAZOLINES AS MDM2 INHIBITORS | 2004 |
|
RU2354649C2 |
| CIS-2,4,5-TRIARYLIMIDAZOLINES | 2004 |
|
RU2319696C2 |
| BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
| VASOPRESSIN V RECEPTOR ANTAGONISTS | 2005 |
|
RU2370497C2 |
| 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROL-2-CARBOXAMIDES AND USE THEREOF FOR PREPARING DRUGS | 2007 |
|
RU2463294C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
